Evaluation of Potential Therapeutic Targets with Experimental or FDA-approved Therapies in Thymic Tumor Microarrays

Thymus epithelial tumors (TETs) are rare malignancies. The standard of care for metastatic TETs is platinum-based chemotherapy. Here, we evaluated the experimental and FDA-approved targets in a large TET tissue array with the hope of identifying a novel therapeutic option.